Tissue engineered vascular grafts — Preclinical aspects

Thomas, Lynda V.; Lekshmi,; Nair, Prabha D.

doi:10.1016/j.ijcard.2012.09.069

Cited by 62 publications

(55 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The anatomic and hemodynamic conditions, as well as blood coagulation are similar to the human vasculature, while the long neck without any bifurcation provides easy access to the common carotid artery, which is a common site for implantation of 4–6 mm diameter vascular constructs [35,36,37]. Moreover, sheep represent a “worst-case model” due to the propensity for accelerated vascular calcification, allowing the assessment of the degenerative processes in a relatively short time period [37].…”

Section: Discussionmentioning

confidence: 99%

Conjugation with RGD Peptides and Incorporation of Vascular Endothelial Growth Factor Are Equally Efficient for Biofunctionalization of Tissue-Engineered Vascular Grafts

Антонова

Seifalian

Kutikhin

et al. 2016

IJMS

View full text Add to dashboard Cite

The blend of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and poly(ε-caprolactone) (PCL) has recently been considered promising for vascular tissue engineering. However, it was shown that PHBV/PCL grafts require biofunctionalization to achieve high primary patency rate. Here we compared immobilization of arginine–glycine–aspartic acid (RGD)-containing peptides and the incorporation of vascular endothelial growth factor (VEGF) as two widely established biofunctionalization approaches. Electrospun PHBV/PCL small-diameter grafts with either RGD peptides or VEGF, as well as unmodified grafts were implanted into rat abdominal aortas for 1, 3, 6, and 12 months following histological and immunofluorescence assessment. We detected CD31+/CD34+/vWF+ cells 1 and 3 months postimplantation at the luminal surface of PHBV/PCL/RGD and PHBV/PCL/VEGF, but not in unmodified grafts, with the further observation of CD31+CD34−vWF+ phenotype. These cells were considered as endothelial and produced a collagen-positive layer resembling a basement membrane. Detection of CD31+/CD34+ cells at the early stages with subsequent loss of CD34 indicated cell adhesion from the bloodstream. Therefore, either conjugation with RGD peptides or the incorporation of VEGF promoted the formation of a functional endothelial cell layer. Furthermore, both modifications increased primary patency rate three-fold. In conclusion, both of these biofunctionalization approaches can be considered as equally efficient for the modification of tissue-engineered vascular grafts.

show abstract

Section: Discussionmentioning

confidence: 99%

Conjugation with RGD Peptides and Incorporation of Vascular Endothelial Growth Factor Are Equally Efficient for Biofunctionalization of Tissue-Engineered Vascular Grafts

Антонова

Seifalian

Kutikhin

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…Autologous grafts remain the gold standard for repair of small vessels, but their availability may be limited and their harvest increases patient morbidity [4]. Key characteristics of an ideal vessel substitute include mechanical compliance for prevention of restenosis and hyperplasia, physical resilience for long-term patency, antithrombogenicity for clot inhibition, antifouling for protection of mechanical or chemical properties, and tailored degradation profiles to match gradual substitution with cellularized matrix [5, 6]. …”

Section: Introductionmentioning

confidence: 99%

Development and evaluation of elastomeric hollow fiber membranes as small diameter vascular graft substitutes

Mercado-Pagán

Kang

Findlay

et al. 2015

Materials Science and Engineering: C

View full text Add to dashboard Cite

Engineering of small diameter (<6 mm) vascular grafts (SDVGs) for clinical use, remains a significant challenge. Here, elastomeric polyester urethane (PEU)-based hollow fiber membranes (HFM) are presented as an SDVG candidate to target the limitations of current technologies and improve tissue engineering designs. HFMs are fabricated by a simple phase inversion method. HFM dimensions are tailored through adjustments to fabrication parameters. The walls of HFMs are highly porous. The HFMs are very elastic, with moduli ranging from 1–4 MPa, strengths from 1–5 MPa, and max strains from 300–500%. Permeability of the HFMs varies from 0.5–3.5×10−6 cm/s, while burst pressure varies from 25 to 35 psi. The suture retention forces of HFMs are in the range of 0.8 to 1.2 N. These properties match those of blood vessels. A slow degradation profile is observed for all HFMs, with 71 to 78% of the original mass remaining after 8 weeks, providing a suitable profile for potential cellular incorporation and tissue replacement. Both human endothelial cells and human mesenchymal stem cells proliferate well in the presence of HFMs up to 7 days. These results demonstrate a promising customizable PEU HFMs for small diameter vascular repair and tissue engineering applications.

show abstract

“…These results clearly indicated the need to mask ECM proteins in order to avoid platelet adhesion and thrombi formation. In this context, recellularizing scaffolds with host ECs prior to implantation or treatment of the inner lining with heparin may be a useful approach (24). By contrast, all animals receiving PVA BVSs survived until the time of sacrification (12 months).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of vascular grafts based on polyvinyl alcohol cryogels

Conconi

Borgio

Liddo

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

The present study designed and developed blood vessel substitutes (BVSs) composed of polyvinyl alcohol (PVA) cryogels. The in vitro results demonstrated that the coating of the polymer with lyophilized decellularized vascular matrix (DVM) greatly enhanced the adhesion of human umbilical vein endothelial cells (HUVECs). However, when PVA̸DVM BVSs were implanted into the abdominal aorta of Sprague‑Dawley rats, DVM was identified as a highly thrombogenic surface resulting in the mortality of all animals 3‑4 days after surgery. By contrast, all rats implanted with PVA survived and were sacrificed after 12 months. The luminal surface of the explanted grafts was completely covered by endothelial cells and the inner diameter was similar to that of the original vessel. In conclusion, the present study indicated that PVA may be considered as a promising biomaterial for the fabrication of artificial vessels.

show abstract

Tissue engineered vascular grafts — Preclinical aspects

Cited by 62 publications

References 90 publications

Conjugation with RGD Peptides and Incorporation of Vascular Endothelial Growth Factor Are Equally Efficient for Biofunctionalization of Tissue-Engineered Vascular Grafts

Conjugation with RGD Peptides and Incorporation of Vascular Endothelial Growth Factor Are Equally Efficient for Biofunctionalization of Tissue-Engineered Vascular Grafts

Development and evaluation of elastomeric hollow fiber membranes as small diameter vascular graft substitutes

Evaluation of vascular grafts based on polyvinyl alcohol cryogels

Contact Info

Product

Resources

About